AFFX Affymetrix, Inc.

Affymetrix Inc. (NASDAQ:AFFX) today announced the full commercial launch of its complete Cytogenetic Solution, which combines the high-density SNP Array 6.0 with a simple assay and intuitive software. The microarray-based solution provides cytogenetic researchers with an efficient and accurate method of detecting chromosomal abnormalities associated with congenital diseases such as autism and mental retardation. The Affymetrix Cytogenetic Solution was designed to discover more causative aberrations across the entire genome compared to other microarray platforms and traditional karyotyping techniques. The solution delivers copy number and loss of heterozygosity (LOH) information, which enables research scientists to identify uniparental disomies � genetic abnormalities that are frequent in many congenital diseases. The introduction of the Affymetrix Cytogenetic Solution has been positively received by customers, many of whom have already successfully deployed these products in everyday practice. Laboratory Corporation of America Holdings (LabCorp) (NYSE:LH) began offering high-resolution cytogenetic services based on the Affymetrix Whole-Genome Sampling Analysis Assay in January 2008. �Affymetrix� continued advances in the availability of whole-genome array technology offer physicians an unprecedented ability to diagnose their patients with developmental disorders, autism and other clinically significant changes,� said Myla P. Lai-Goldman, M.D., executive vice president, chief scientific officer and medical director of LabCorp. �We are very pleased to have the Affymetrix Cytogenetic Solution in our laboratory,� said Lisa Shaffer, Ph.D., director, Signature Genomic Laboratories. �This platform will give us the ability to perform high-resolution copy number analysis and evaluate LOH at the same time. We anticipate that this assay will also be useful in characterizing the breakpoints of previously known chromosome abnormalities.� �The Affymetrix Cytogenetic Solution has provided clinical cytogeneticists with a powerful tool that will greatly enhance our diagnostic capability,� said Brynn Levy, Ph.D., associate professor of clinical pathology and director, Clinical Cytogenetics Laboratory at College of Physicians and Surgeons of Columbia University. �We are entering the realm where imbalances from �genome to gene� can be detected. As we gather and catalog precise information regarding the gene content of deletions and duplications in conjunction with well-characterized clinical information, our ability to make accurate genotype-phenotype predictions will be greatly improved.� �We are very pleased that prominent industry leaders are rapidly adopting our GeneChip� technology for this important new application,� said Kevin King, president of Affymetrix. �The Affymetrix Cytogenetic Solution was developed through extensive lead-user involvement and we expect it to become the gold-standard tool for cytogenetics.� The Affymetrix Cytogenetic Solution Includes: High-density SNP Array 6.0 � Detects both submicroscopic and large chromosomal abnormalities with clear definition of breakpoints. Simple and robust Cytogenetics Copy Number Assay � Offers flexibility for low-and high-throughput users. Intuitive Genotyping Console 2.1 software � Makes it easy to move from copy number and LOH data to results. For more information about the Affymetrix Cytogenetic Solution, please visit: http://www.affymetrix.com/genechip/cyto.affx. About Affymetrix Affymetrix GeneChip� microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world�s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 11,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are �forward-looking statements� within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix� �expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the Affymetrix Cytogenetic Solution discussed in this press release; risks of the company�s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix� Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix� expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered trademarks owned or used by Affymetrix Inc.